Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM patients achieved ...

Pharma presented results showing statistically significant improvements in clinical outcomes as compared to placebo for time ...

The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...

Researchers at ACC suggested stratifying by age and TTR variant, plus cascade testing, could help identify those likely to ...

Researchers at the American College of Cardiology's annual meeting used proteomic approaches to uncover dysregulated signaling pathways in the disease.

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.

Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

Amvuttra operates via RNA interference (RNAi), a groundbreaking technology that inhibits the production of the TTR protein in ...

President Donald Trump continues to warn of tariffs on the pharmaceutical industry; Susan Monarez replaces Dave Weldon as CDC ...

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its price target increased by equities researchers at JPMorgan Chase & ...